Loading
BIO-TECHNE Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 11 May 2022.
BIO-TECHNE Corp: what insiders have been doing
This page follows insider dealings at BIO-TECHNE Corp as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Minneapolis. The group dates from 1976. Over the twelve months to 18 October 2026, 48 filings were filed, from 14 insiders.
The flow runs one way only: 1 sale worth €99k, from 1 insider, and no purchase. One trade stands out by size: a sale of €99k from Herr Amy E., disclosed on 19 February 2026.
The median gap between a trade and its publication by SEC (Form 4) is 3 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Compared with its exchange (5,812 companies, median 19 filings), a count of 48 filings is above the norm. Since 2016, the database holds 1 purchase and 12 sales by insiders of the company. In its latest annual report filed with the SEC (10-K, fiscal year ended 30 June 2026), the company reported revenue of 1.22 bn USD and net income of 181.9 m USD, with a dividend of 0.32 USD per share.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Cytosorbents Corp also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
194
Thresholds
n/a
Buy Volume
€100,413
1 ops. · all time
Sell Volume
€14M
12 ops. · all time
Who traded when
BuySaleAmy E. Herr1 sale
Since the insiders bought
- -6.8%Entry US$87.22 · Close at T+365 US$81.30
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate BIO-TECHNE Corp Hold (neutral), based on 10 analysts. Average price target: US$70.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 11,069 of 24,158 companies
53.7
score / 100
Value34
Quality73
FCF yld2.3%
Earn yld1.6%
EV/EBITDA33.5x
ROE9.0%
Gross mgn66%
Net mgn15%
Debt/EBITDA0.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended June 2026 · cache
US$72.48
Analyst consensus
10 analystsHold
US$50.00Target US$70.50(-3%)US$73.00
Income statement
RevenueUS$1.2B
Gross profitUS$799.1M66% margin
EBITDAUS$347.7M29% margin
Net incomeUS$181.9M15.0% margin
Valuation
PER (trailing)62.5x
PER (forward)31.3x
P/Book5.4x
Beta1.30
Balance sheet & cash
Market capUS$11.4B
Total debtUS$289.1M
Free Cash FlowUS$263.2M
Debt / Equity14%
Profitability & ownership
ROE9.0%
ROA6.7%
% insiders0.3%
% institutions114.7%
Last declaration on 30 September 2026
Declarations194 total
15,940 shares0Common StockSEC:0000914190-26-000142:0
5,562 shares@ US$72.510.0035% mcap21.9% of flowCommon StockSEC:0000914190-26-000142:1
15,940 shares0Common StockSEC:0000914190-26-000139:0
5,559 shares@ US$72.550.0035% mcap25.0% of flowCommon StockSEC:0000914190-26-000139:1
21,470 shares0Common StockSEC:0000914190-26-000122:0
589 shares0Common StockSEC:0000914190-26-000113:0
5,423 shares0Common StockSEC:0000914190-26-000114:0
4,350 shares0Common StockSEC:0000914190-26-000116:0
6,416 shares0Common StockSEC:0000914190-26-000120:0
9,779 shares0Common StockSEC:0000914190-26-000121:0
213 shares@ US$72.400.0001% mcap5.4% of flowCommon StockSEC:0000914190-26-000113:1
1,947 shares@ US$72.400.0012% mcap83.7% of flowCommon StockSEC:0000914190-26-000114:1
1,343 shares@ US$72.400.0008% mcap46.1% of flowCommon StockSEC:0000914190-26-000116:1
1,976 shares@ US$72.400.0012% mcap27.1% of flowCommon StockSEC:0000914190-26-000120:1
4,310 shares@ US$72.400.0027% mcap1.0% of flowCommon StockSEC:0000914190-26-000121:1
10,821 shares@ US$72.400.0068% mcap5.5% of flowCommon StockSEC:0000914190-26-000122:1
51,024 shares@ US$72.030.032% mcap11.8% of flowCommon StockSEC:0000914190-26-000108:1
62,068 shares@ US$47.600.026% mcap9.5% of flowCommon StockSEC:0000914190-26-000108:0
28,686 shares@ US$72.070.018% mcap14.6% of flowCommon StockSEC:0000914190-26-000106:1
35,000 shares@ US$47.600.015% mcap11.8% of flowCommon StockSEC:0000914190-26-000106:0
344 shares@ US$71.770.0002% mcap11.8% of flowCommon StockSEC:0000914190-26-000104:1
448 shares@ US$47.600.0002% mcap10.2% of flowCommon StockSEC:0000914190-26-000104:0
600 sharesCommon StockSEC:0000914190-26-000096:0
216 shares@ US$49.770.0001% mcap6.3% of flowCommon StockSEC:0000914190-26-000096:1
311 shares@ US$55.020.0002% mcap10.0% of flowCommon StockSEC:0000914190-26-000083:1
25 of 194 declarations
About BIO-TECHNE Corp
BIO-TECHNE Corp (ticker: TECH) is a U.S.-based life sciences company listed on NASDAQ in the United States. For French-speaking investors in France, Belgium, and Switzerland, Bio-Techne stands out as a high-quality tools and diagnostics provider positioned at the intersection of basic research, translational biology, and precision diagnostics. The company is headquartered in Minnesota and operates globally through 34 locations with approximately 3,100 employees. Its portfolio includes more than 500,000 products, spanning reagents, bioactive proteins, analytical instruments, and diagnostic solutions. ([bio-techne.com](https://www.bio-techne.com/about/about-bio-techne?utm_source=openai))
Bio-Techne is a long-established franchise in the life-science tools industry; the company says it is celebrating 50 years in 2026, underscoring its long operating history in biomedical research tools. Over time, it has built a recognized position with academic labs, biopharma customers, and clinical diagnostic users, supported by a broad catalog and specialized scientific know-how. Its product depth and scientific reputation are key differentiators in a market where trust, reproducibility, and assay performance matter. ([investors.bio-techne.com](https://investors.bio-techne.com/press-releases/detail/533/bio-techne-releases-third-quarter-fiscal-2026-results?utm_source=openai))
Read moreShow less
The company’s business model is organized around three customer-facing brands: R&D Systems for reagents and bioactive proteins, Bio-Techne Spatial for spatial biology, and Bio-Techne Diagnostics for diagnostic and clinical workflows. This structure reflects a deliberate strategy to cover the full scientific pathway from discovery to translational research and clinical decision-making. Bio-Techne also highlights platforms such as Ella and a growing set of spatial biology and proteomic analysis offerings, reinforcing its exposure to higher-value, innovation-led end markets. ([bio-techne.com](https://www.bio-techne.com/about/about-bio-techne?utm_source=openai))
From a competitive perspective, Bio-Techne benefits from a premium brand in reagents and assays, a large installed base, and a diversified customer mix across pharma, biotech, and academia. Its business is not immune to cycles in biotech funding, but the company has recently described resilient demand from large pharma, stabilization in U.S. academic markets, and continued caution among emerging biotech customers. That mix gives the stock a balanced profile: structurally attractive long-term growth, but with short-term sensitivity to research spending trends. ([investors.bio-techne.com](https://investors.bio-techne.com/press-releases/detail/533/bio-techne-releases-third-quarter-fiscal-2026-results?utm_source=openai))
Recent headlines have focused on portfolio optimization and product innovation. Bio-Techne completed the divestiture of its Exosome Diagnostics business, introduced a streamlined brand architecture, and launched new ultra-sensitive assays on the Ella automated benchtop platform. Management has also emphasized productivity and cost-containment initiatives, while continuing to invest in key growth pillars such as spatial biology and proteomics. Overall, Bio-Techne appears to be refining its portfolio toward higher-growth, higher-margin scientific tools and diagnostics, which is relevant for investors seeking exposure to the Healthcare & Pharma sector on NASDAQ in the United States. ([investors.bio-techne.com](https://investors.bio-techne.com/press-releases/detail/513/bio-techne-releases-first-quarter-fiscal-2026-results/?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
